Patni Family Reboots Business Strategy with Major Investment in Branded Generics through Raay Neo

Raay Neo Pharma: Patni Family Enters India's Branded Generics Market

The Patni family, pioneers of IT outsourcing, is venturing into India's crowded branded generics market with ambitious plans. Amit Patni, the founder director of Raay Global Investments, has launched Raay Neo Pharma to build a formulations business from scratch.

Raay Neo Pharma was launched in April and is positioned as a long-term brand play. The company has already introduced around 90 products to the market, with plans to increase this number to 200 formulations over two to three years. The goal is to expand across states and therapies while pushing into exports.

The company has launched with a multi-specialty portfolio spanning antibiotics, cardio-diabetes, respiratory, gastro, and dermatology, targeting both acute and chronic segments. Raay Neo Pharma is investing in R&D and differentiated formulations to build scale over time.

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

Table: Raay Neo Pharma's Expansion Plans

Raay Neo Pharma plans to focus on tier-2 and 3 markets, where the company sees an opportunity to build a trusted brand amid fragmentation in the branded generics space. The company estimates that there are many small regional players that lack the capital or consistent quality to compete with larger players.

To achieve its goals, Raay Neo Pharma is using an operating model that combines in-house branded formulations with third-party manufacturing partnerships. This allows the company to maintain quality control while achieving a faster go-to-market. The firm is also investing in R&D and differentiated formulations, alongside exploring backward integration into manufacturing over time to improve costs and margins.

Read also: Suzlon to Expand Business Scope Beyond Wind Energy, Invests Rs 500 Crore in New Subsidiary This Fiscal Year

Raay Neo Pharma is positioning itself as a quality-led, mid-priced branded generics player, aiming to build trust with doctors and ensure consistency of supply. The company is not pricing very low but not very high either, allowing it to maintain a balance between affordability and profitability.

The entry into pharma follows a strategic pivot at the family office level after evaluating multiple sectors, including APIs and manufacturing. Amit Patni said that the decision was driven by India's consumption growth and healthcare demand, alongside the ability to build a scalable brand.

The Patni family has a long history in the IT sector, founding Patni Computers in 1976 and exiting to iGate in a $1.2-billion deal in 2011. Since then, Amit Patni has managed a family office platform — Raay Global Investments — and backed multiple ventures and funds, including early-stage and consumer investments.